[ 18 F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma
Hematological Oncology · 2023
DOI: 10.1002/hon.3171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2023. Verfasst von Laura Lavinia Travaini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nuclear Medicine, IEO European Institute of Oncology, IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
To evaluate the association between radiomic features (RFs) extracted from 18 F‐FDG PET/CT ( 18 F‐FDG‐PET) with progression‐free survival (PFS) and overall survival (OS) in diffuse large‐B‐cell lymphoma (DLBCL) patients eligible to first‐line chemotherapy. DLBCL patients who underwent 18 F‐FDG‐PET prior to first‐line chemotherapy were retrospectively analyzed. RFs were extracted from the lesion showing the highest uptake. A radiomic score to predict PFS and OS was obtained by multivariable Elastic Net Cox model. Radiomic univariate model, clinical and combined clinical‐radiomic multivariable models to predict PFS and OS were obtained. 112 patients were analyzed. Median follow‐up was 34.7 months (Inter‐Quartile Range (IQR) 11.3–66.3 months) for PFS and 41.1 (IQR 18.4–68.9) for OS. Radiomic score resulted associated with PFS and OS ( p < 0.001), outperforming conventional PET parameters. C‐index (95% CI) for PFS prediction were 0.67 (0.58–0.76), 0.81 (0.75–0.88) and 0.84 (0.77–0.91) for clinical, radiomic and combined clinical‐radiomic model, respectively. C‐index for OS were 0.77 (0.66–0.89), 0.84 (0.76–0.91) and 0.90 (0.81–0.98). In the Kaplan‐Meier analysis (low‐IPI vs. high‐IPI), the radiomic score was significant predictor of PFS ( p < 0.001). The radiomic score was an independent prognostic biomarker of survival in DLBCL patients. The extraction of RFs from baseline 18 F‐FDG‐PET might be proposed in DLBCL to stratify high‐risk versus low‐risk patients of relapse after first‐line therapy, especially in low‐IPI patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nuclear Medicine, IEO European Institute of Oncology, IRCCS, Milan, Italy.
- Medical Physics Unit, IEO European Institute of Oncology IRCCS, Milan, Italy.
- Oncohematology Division, IEO European Institute of Oncology IRCCS, Milan, Italy.
- Department of Health Sciences, University of Milan, Milan, Italy.
- Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
ORCID-Profile: Laura Lavinia Travaini, Enrico Derenzini, Lighea Simona Airò Farulla
Zitieren
APA
Travaini, L. L., Botta, F., Derenzini, E., Lo Presti, G., Ferrari, M. E., Airò Farulla, L. S., Radice, T., Mazzara, S., Tarella, C., Pileri, S., Raimondi, S., & Ceci, F. (2023). [ 18 F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.3171
Vancouver
Travaini LL, Botta F, Derenzini E, Lo Presti G, Ferrari ME, Airò Farulla LS, et al. [ 18 F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma. Hematological Oncology. 2023. doi:10.1002/hon.3171
BibTeX
@article{Travaini2023,
author = {Travaini, Laura Lavinia and Botta, Francesca and Derenzini, Enrico and Lo Presti, Giuliana and Ferrari, Mahila Esmeralda and Airò Farulla, Lighea Simona and Radice, Tommaso and Mazzara, Saveria and Tarella, Corrado and Pileri, Stefano and Raimondi, Sara and Ceci, Francesco},
title = {[ 18 F]‐FDG PET radiomic model as prognostic biomarker in diffuse large B‐cell lymphoma},
journal = {Hematological Oncology},
year = {2023},
doi = {10.1002/hon.3171}
}
EUVIMED